Prevalence of SARS-CoV2 antibodies in false positive serology
| Ig type | N | % |
|---|---|---|
| IgM+ | 6 | 42.86 % |
| IgG+ | 6 | 42.86 % |
| IgG+ and IgM+ | 2 | 14.28 % |
Prevalence of SARS-CoV2 antibodies in false positive serology
| Ig type | N | % |
|---|---|---|
| IgM+ | 6 | 42.86 % |
| IgG+ | 6 | 42.86 % |
| IgG+ and IgM+ | 2 | 14.28 % |
MGC contributed to data collection, study design and paper draft; MS performed the analysis and contributed to study design and paper draft; RV, FC, GDG and PC organized the database and revised sections of the manuscript; GS conceptualized and supervised the entire work.
The authors declare that they have no conflicts of interest.
All the procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent to participate in the study was obtained from all participants.
Not applicable.
All relevant data is contained within the manuscript.
Not applicable.
© The Author(s) 2021.